Recruiting
Phase 2

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

Sponsor:

The Methodist Hospital Research Institute

Code:

NCT05241340

Conditions

Urothelial Carcinoma Bladder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sasanlimab

Stereotactic Body Radiation Therapy

Radical Cystectomy + pelvic lymph node dissection + urinary diversion

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information